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Characterization of signaling pathways that control cancer stem cells may lead to more effective treatments
against cancer. In this issue of Cell Stem Cell, a study by Charles et al. (2010) identifies the NO and Notch
pathways as important regulators of the perivascular niche of cancer stem cells in glioma.The concept of cancer stem cells (CSCs),
also called cancer-initiating cells, is pro-
viding new perspectives in cancer
research. The hypothesis that cells within
the heterogeneous tumor mass have
characteristics of stem cells and are
responsible for tumor initiation, recur-
rence, and resistance to therapy is redi-
recting the therapeutic and research
efforts against cancer. According to this
model, CSC elimination is required in
order to eradicate tumors, and thus,
understanding the molecular pathways
involved in the control of CSCs is critical.
To this end, identifying specific thera-
peutic compounds that can effectively
eliminate this cell type may point to new
therapeutic strategies against cancer
(Visvader and Lindeman, 2008; Zhou
et al., 2009). Following this approach,
Charles et al. (2010) identify a mechanism
governing glioma CSCs in this issue of
Cell Stem Cell, and in doing so, may
open a new avenue for therapeutic
intervention.
Normal stem cells are usually localized
in specialized niches in which other
cell types and extracellular components
provide extrinsic regulatory signals that
control the stem cell fate. Normal neural
stem cells have been shown to lie in
a vascular niche in which endothelial cells
regulate stem cell self-renewal (Louissaint
et al., 2002; Palmer et al., 2000). Similarly,
in tumors such as gliomas, CSCs can
also be located in specific niches sur-
rounding tumor vasculature, suggesting
that in addition to normal stem cells,
CSC fates can also be controlled by the
immediate vascular microenvironment.
Notably, recent work has shown that
the perivascular niche controls the
self-renewing capacity of glioma CSCs
through endothelial cell-secreted factors
(Calabrese et al., 2007). However, theidentity of the factors secreted by the
endothelial cells, as well as the pathways
involved in controlling CSC self-renewal,
remain poorly characterized. The work of
Holland and colleagues (Charles et al.,
2010) now sheds light onto the processes
involved in the control of CSCs by the
perivascular niche.
In their current study, Charles et al.
(2010) used a mouse model of PDGF-
induced glioma to demonstrate that nitric
oxide (NO) secreted from endothelial cells
promotes a stem cell-like character in
cells present in the perivascular niche.
Through the analysis of cultured glioma
cells, the authors initially found that NO
induced Notch activity. To specifically
analyze cells with stem cell characteris-
tics present in the tumors, Holland and
colleagues used side population (SP)
analysis, originally applied to isolate
hematopoietic stem cells by means of
their ability to efflux Hoechst fluorescent
dyes via ABC transporters (Goodell
et al., 1996). Holland and colleagues
previously reported that SP cells from
PDGF-induced mouse gliomas have
tumor initiating capacities and are en-
riched for glioma CSCs (Bleau et al.,
2009). Here, the authors found that NO
activated Notch that, in turn, induced the
SP phenotype and increased the neuro-
sphere-forming capacity of glioma cells.
Using RNA interference, inhibitors of NO
activity (LNAME), and gamma secretase
inhibitors that target Notch signaling, the
authors demonstrated that the induction
of the SP phenotype by NO required
Notch activation. They also showed that
transgenic ablation of eNOS, the enzyme
responsible for NO synthesis, repressed
tumor formation and interfered with Notch
activity. The authors went on to discern
the molecular mechanisms involved in
the regulation of Notch activity by NOCell Stem Celland found that NO drives Notch signaling
via the cGMP/PKG pathway (Figure 1).
Importantly, the authors showed that
transient activation of the NO pathway
in vitro not only enhanced the SP popu-
lation phenotype but also increased
the tumor initiating capacity of the cells
in vivo. That is, cells treated with NO prior
to inoculation in the brain of immunocom-
promised mice generated tumors with
both higher incidence and shorter latency.
The authors replicated these findings
using human glioma cells. Cells from
one patient with a PDGF receptor ampli-
fied glioblastoma displayed the same
response to NO as the PDGF-induced
mouse glioma cells; NO enhanced Notch
activity, the SP population, and the tumor-
initiating capacity of the human cells.
These results indicated that NO enriched
the cell culture for CSCs.
It would also be of interest to determine
whether exposure to NO regulates CSCs
through the induction of CSC self-renewal
and blockade of differentiation or, alterna-
tively, if NO promotes the conversion of
non-CSCs into CSCs by somehow elicit-
ing stem cell traits in a non-CSC popula-
tion of tumor cells. The latter case has
important implications. It would argue
against a hierarchical model for CSCs
and would imply that agents against
CSCs would not be effective in isolation
since non-CSCs could restore the CSC
pool. A combination of agents targeting
both CSCs and non-CSCs would be
more beneficial.
A number of cell surface markers,
including CD133, have proved useful for
the isolation of subsets of cells enriched
for CSCs in different tumor types, and
specifically in gliomas (Visvader and Lin-
deman, 2008). One important question
that remains to be determined is to








Figure 1. NO Induces Stem Cell-like Characteristics in the
Perivascular Niche
Endothelial cells in PDGF-induced gliomas secrete NO that promotes stem
cell-like characteristics in cells present in the perivascular niche through the
activation of the cGMP/PKG pathway and Notch. Endothelial cells are repre-
sented in red, CSCs are represented in blue, and non-CSCs are represented
in green.
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Previewsenriched for CSCs based on
their dye-exclusion capacity
rather than on cell-surface
phenotype, overlaps with
previously isolated CSC pop-
ulations. Moreover, a sub-
stantial heterogeneity may
exist between CSC popu-
lations of different tumors.
Although vascular niches
have been identified for
numerous normal and tumor
stem cell populations, it
remains likely that CSCs
across tumors may be regu-
lated by distinct niche-
specific pathways or even be
niche independent. This
concept is of major relevance
for therapeutic interventions
since it implies that CSCs
of a particular tumor need
to be well characterized to
identify specific and effective
treatments.
As discussed above, Hol-
land and colleagues found
that the control of CSCs bythe NO/Notch signaling pathway was
conserved in a sample from a patient
with a PDGF receptor amplified glioblas-
toma. Although these results are encour-
aging from a therapeutic perspective,
analyzing samples from more patients
would be required, first, to provide
stronger evidence that the NO/Notch
pathway plays a role in human glioma
and, second, to find markers that corre-
late with a response to anti-NO treat-
ments. It would also be of importance
to investigate gliomas with no PDGFR
amplification in order to understand
whether the identified mechanisms are
specific to PDGFR-amplified tumors
and if so, to uncover the reason for that
specificity.98 Cell Stem Cell 6, February 5, 2010 ª2010Work over recent years has shown that
several signaling pathways (Wnt, Shh,
Notch, TGF-b, LIF and others) can reg-
ulate the CSC compartment and that
compounds targeting these pathways
offer efficient anti-CSC activity (Ikushima
et al., 2009; Pen˜uelas et al., 2009; Vis-
vader and Lindeman, 2008; Zhou et al.,
2009). The work of Charles et al. intro-
duces yet another player in the game
and indicates that NO inhibitors might be
effective against CSCs by interfering
with the regulation provided by the peri-
vascular niche. Important remaining
questions include how NO inhibitors
affect normal stem cells and which CSC
or tumor markers might predict whether
CSCs of a particular tumor are controlledElsevier Inc.by NO, implying an efficient
response to NO inhibitors.
The path for developing
agents against CSCs is
just beginning, but the thor-
ough study of the molecular
mechanisms that participate
in CSC regulation holds pro-
mise for the development of
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